Skip to main content
Caplight Logo









InVitria

InVitria

Private
Junction City, KansasHealthcare & Life Scienceshttps://invitria.com

Last Round

Grant

Oct 23, 2017

Total Funding Raised

$9.45M

Company Overview

InVitria is a biotechnology company that develops and manufactures recombinant, animal-origin-free proteins for biopharmaceutical manufacturing and formulation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

recombinant proteinsAOFanimal-free componentscell culture mediabiomanufacturing ingredientsserum-free mediaplant-based protein expressionchemically defined mediarHSArecombinant albuminrecombinant transferrinvaccine productioncell and gene therapycGMP manufacturingbioprocessingregenerative medicinebiotech reagents

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

InVitria Comparables

Compare InVitria with similar companies based on industry and business-model similarity.

InVitria comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Levprot Bioscience
71%
Cape Bio Pharms
69%
Silvia Bio
58%

InVitria Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 23, 2017
GrantJun 4, 2012
Convertible DebtJun 1, 2011
GrantAug 14, 2009

Key People

Founding team and executive leadership

Scott Deeter

CEO Founder

Founding Team

InVitria Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 5, 2026

    Monthly visitors increased 65% MoM, reaching 5.7K.

  • Jun 1, 2025

    Monthly visitors increased 80% MoM, from 4.1K to 7.4K.

InVitria Filings

Explore SEC and related filing metadata, where available.

InVitria filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about InVitria's valuation, stock price, and market status.

Is InVitria a public or private company?

InVitria is a private company.

What is the current stock price of InVitria?

InVitria is a private company, so its shares have no public market price. Caplight tracks InVitria's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is InVitria worth (valuation)?

Valuation information for InVitria is not publicly available.

Can I buy InVitria stock?

InVitria shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was InVitria's last funding round?

InVitria's most recent funding round was Grant on October 23, 2017.

Who are the main investors in InVitria?

Key investors in InVitria include National Institute of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation, Kansas Bioscience Authority.

Will InVitria IPO soon?

No public IPO plans have been announced for InVitria.

How can I track InVitria secondary market activity?

Caplight tracks bids, offers, and trades in InVitria's shares on secondary markets.

Firmographic Details

HeadquartersJunction City, Kansas
Employee Range20
Year Founded2006
Last FundingOct 23, 2017

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?